NEW YORK – Personal Genome Diagnostics (PGDx) said on Wednesday that it has entered a strategic collaboration with the Mayo Clinic to improve clinical diagnostic oncology solutions.
As part of the collaboration, the partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications, combining Mayo Clinic's clinical knowledge and expertise in oncology and PGDx's experience with genomic technology.
"[Mayo Clinic's] deep knowledge of establishing standards of care in oncology, the complexity and volume of cancer cases they see, and their expertise in the implementation of testing in a real-world setting are second to none," PGDx CEO Doug Ward said in a statement. "Collaborating with Mayo Clinic will allow us to better assess the impact that our Elio liquid biopsy and tissue applications will have on improving clinical insights and will advance innovations in next-generation sequencing technology."
Financial details of the collaboration were not disclosed.
In September, PGDx CE-marked the PGDx Elio tissue complete assay.